Denise Myshko

A small clinical trial of pediatric patients with relapsed/refractory acute myeloid leukemia showed efficacy and safety with anti-C-type lectin-like molecule-based chimeric antigen receptor T cells.

After 4 years of treatment with the combination of nivolumab and ipilimumab, the therapy showed durable, long-term overall survival benefit compared with chemotherapy in patients with advanced non‒small cell lung cancer regardless of PD-L1 expression or histology.

Findings from a A phase 3 trial evaluating adjuvant nivolumab following surgery versus placebo demonstrated an improvement in median disease-free survival in patients with muscle-invasive urothelial cancer, according to results from the CheckMate 274 trial presented at the 2021 Genitourinary Cancers Symposium.

After treatment with savolitinib, undetectability of MET Exon 14 in the circulating tumor DNA of patients with non‒small cell lung cancer was found to be associated with prolonged progression-free survival, and overall survival.

In the phase 3 VISION study, treatment with the MET inhibitor, tepotinib showed durable clinical activity as treatment of patients with MET exon 14 skipping non‒small cell lung cancer.

Adjuvant treatment with pertuzumab demonstrated a trend for greater benefit in patients with early breast cancer with a HER2 single-activated pathway determined by molecular subtyping using BluePrint assay.

An analysis from the MURANO trial showed that venetoclax in combination with rituximab led to a more than doubling of time to next treatment compared with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Patients with acute myeloid leukemia in first remission regardless of the number of rounds of prior consolidation therapy had significantly prolonged overall survival and relapse-free survival with azacitidine.

In the treatment landscape of metastatic castration resistant prostate cancer, the introduction of PARP inhibitors as a therapeutic option has led to progress, explained Maha Hussain, MD, in a presentation during the 38th Annual Chemotherapy Foundation Symposium.

Patients with NTRK fusion–positive solid tumors and baseline CNS metastases demonstrated durable intracranial activity with entrectinib, according to results of a small subpopulation analysis presented at the 2020 ESMO Virtual Congress.

Futibatinib demonstrated efficacy and tolerability when administered as treatment of patients with intrahepatic cholangiocarcinoma who harbor FGFR2 fusions/rearrangements, according to interim analysis results presented in a poster during the the European Society of Medical Oncology Virtual Congress 2020

Adding a subcutaneous formulation of daratumumab to the triplet regimen cyclophosphamide, bortezomib, and dexamethasone may hold promise for patients with newly diagnosed light chain amyloidosis who are in urgent need of new treatment options, according to a clinical trial.

In the face of canceled medical meetings this spring, continuing medical education offerings from Physicians’ Education Resource, LLC® were quickly transitioned from an in-person format to virtual presentations that have the ability to reach more medical specialists nationwide.

“In both subgroups, the benefit of veliparib was durable, with an increased probability of remaining progression free at 2 and 3 years compared with placebo,”

"The overall response rate and progression-free survival were significantly improved with pyrotinib plus capecitabine."

"In the phase 1, first-in-human study, we saw encouraging anti-cancer activity in multiple tumor types with G12C, and the toxicities were tolerable."

Encouraging survival outcomes were seen with trametinib in patients with low-grade serous ovarian cancer treated in a phase II/III clinical trial.